Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331188 · ClinicalTrials.gov registry record · Phase 3
Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding
A Phase 3 study of Portal Hypertension and Esophageal Varices, sponsored by Debiovision.
- Completed
- Registry status
- Phase 3
- Development phase
- 70
- Enrollment target
- 19
- Study locations
NCT00331188: Completed Phase 3 study of Portal Hypertension and Esophageal Varices, sponsored by Debiovision.
NCT00331188 is a Phase 3 study of Portal Hypertension and Esophageal Varices that has completed, run by Debiovision. The registered enrollment target is 70 participants, below the 201-participant average among 9 other Portal Hypertension trials with a reported enrollment target (65% lower). The trial reports 19 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00331188, a Phase 3 study of Portal Hypertension and Esophageal Varices, has completed, sponsored by Debiovision.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 70 participants
- Enrollment target
- 19
- Study locations
Study Summary
The main objective of this study is to determine the efficacy of early administration of Sanvar® in combination with endoscopic treatment for the control of acute variceal bleeding.
Conditions Studied
Interventions
- DRUG Sanvar® (vapreotide)
Study Locations (19)
Alabama
- UAB Liver Center - Birmingham
- Alabama Liver & Digestive Specialists - Montgomery
New York
- Weill Medical College of Cornell University - New York
- Columbia University Medical Center - New York
Arizona
- Mayo Clinic - Scottsdale
California
- University of California at San Diego - San Diego
Colorado
- University of Colorado Health Sciences Center - Denver
Connecticut
- Yale University School of Medicine - New Haven
Florida
- Mayo Clinic - Jacksonville
Illinois
- Northwestern University, The Feinberg School of Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00331188 record still lists
NCT00331188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 201-participant average among 9 other Portal Hypertension trials with a reported enrollment target (65% lower).
The record links to 4 conditions, with Portal Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Sanvar® (vapreotide) is the first listed.
NCT00331188 lists 19 locations in 17 states (Alabama, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT00331188 about?
NCT00331188 is a clinical study titled "Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding". The main objective of this study is to determine the efficacy of early administration of Sanvar® in combination with endoscopic treatment for the control of acute variceal bleeding.
What is the current status of trial NCT00331188?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2006-05. Estimated completion is 2008-07.
What conditions does trial NCT00331188 study?
This clinical trial studies the following conditions: Portal Hypertension, Esophageal Varices, Gastric Varices, Esophageal Bleeding.
What interventions are being tested in trial NCT00331188?
The interventions under investigation include: Sanvar® (vapreotide) (DRUG).
Who is sponsoring clinical trial NCT00331188?
This trial is sponsored by Debiovision, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00331188 being conducted?
This trial has 19 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Portal Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00331188's enrollment target sits among peer trials
70 5th of 9 higher than 5 of 9 other Portal Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Portal Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
RECRUITING · Phase 3
-
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis
COMPLETED · Phase 3
-
Prevention of Esophageal Varices by Beta-Adrenergic Blockers
COMPLETED · Phase 3
-
Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension
RECRUITING · NA
-
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
RECRUITING
-
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia